Browsing by Author "Basturk, Bilkay"

Filter results by typing the first few letters
Now showing 1 - 17 of 17
  • No Thumbnail Available
    Item
    A 3-Year Program From the Turkish Ministry of Health for Standardization and Service Quality Improvement of Transplant and Tissue Typing Laboratories in Turkey
    (2017) Basturk, Bilkay; Mercan, Ferzane; Kapuagasi, Arif; Oguz, Fatma Savran; Demirel, Gulderen Yanikkaya; Oktem, Ibrahim Mehmet Ali; Aslan, Avsar; Yilmaz, Serap; Okumus, Nurullah; Gumus, Eyup; https://orcid.org/0000-0002-8784-1974; 28661311; AAD-6918-2021
  • No Thumbnail Available
    Item
    Anti-HLA Antibody Levels Are Associated With the Risk of Graft Failure After Allogeneic Hematopoietic Stem Cell Transplant
    (2017) Basturk, Bilkay; Kasar, Mutlu; Yeral, Mahmut; Kavuzlu, Miray; 0000-0002-9580-628X; 0000-0003-3856-7005; 0000-0002-9288-942X; 0000-0002-8784-1974; 28260472; ABC-4148-2020; AAE-6201-2021; AAL-3906-2021; AAE-2689-2021; AAD-6918-2021
    Objectives: Allogeneic hematopoietic stem cell trans plant provides a curative treatment for a considerable amount of hematologic diseases, and it is widely used today. Successful allogeneic stem cell transplant can be compromised by treatment-related toxicity, graft-versus-host disease, infectious complications, disease relapse, and graft failure. Primary graft failure is an important cause of hematopoietic stem cell transplant failure. Primary graft failure correlates with the level of complement-binding, donor-specific anti-HLA anti bodies prior to transplant. Material and Methods: We evaluated 15 patients who underwent hematopoietic stem cell transplant using peripheral blood stem cells in terms of graft failure and anti-HLA antibody levels before transplant. All were treated between January 2015 and June 2016. Pretreatment serum anti-HLA class I and anti-HLA class II antibody levels were measured in all patients. Results: Anti-HLA class I antibodies were present in 7 patients (46.6%) and anti-HLA class II antibodies in 8 (53.3%). All three patients who developed primary graft failure were anti-HLA-positive. Conclusions: Anti-HLA antibodies are a significant cause of graft failure. It is a situation that must be understood with caution. Our results support the considerations that allogeneic hematopoietic stem cell transplant, especially when a fully compatible sibling donor is not present, should include screening of donor-specific antibodies of alternative donors and desensitization therapy for allosensitized patients before transplant.
  • No Thumbnail Available
    Item
    Association Between Panel Reactive Antibody and Antiendothelial Cell Antibody Positivity in Kidney Transplant Patients
    (2015) Basturk, Bilkay; Kantaroglu, Bircan; Noyan, Z. Aytul; Yildirim, Sedat; Sariturk, Cagla; 0000-0002-8784-1974; 0000-0002-5735-4315; 0000-0002-4130-1059; 25894170; AAD-6918-2021; AAF-4610-2019; AAS-7129-2021
    Objectives: Endothelium is the major tissue for hyperacute and acute rejection. Binding of antibody to endothelium activates several immunologic mechanisms. Antiendothelial cell antibodies are a group of nonhuman leukocyte antigen antibodies that may play a role in the induction of an immunologic reaction that triggers inflammation. The aim of this study was to investigate whether there was an association between antiendothelial cell antibody positivity and panel reactive antibody positivity in renal transplant patients. Materials and Methods: In this study, we investigated the association between antiendothelial cell antibodies and panel reactive antibody Class I class II crossmatch positivity in patients, and compared these results with results from 100 healthy volunteers. All serum samples were analyzed by bead-based technology for calculated panel reactive antibody positivity; in addition, slides were used, each containing human umbilical vein endothelial cells and capillary-rich tissue for antiendothelial cell antibody positivity. Results: Antiendothelial cell antibodies was positive in 48 of 89 patients (panel reactive antibody Class I class II negative), 22 of 35 patients (class l-positive), 25 of 39 patients (class II-positive), 26 of 40 (class I-class II positive), and 37 of 57 serologic and flow cytometry crossmatch-positive patients (P <= .016), and ultimately, in 122 of 205 patients and 25 of 100 volunteers (P <= .001). Antiendothelial cell antibody positivity was more frequent in panel reactive antibody-positive than negative patients and the control group. Conclusions: Binding of antiendothelial cell antibodies to endothelial cells may activate complement by the classical pathway and cause up-regulation of adhesion molecules. This study questioned the antigenic specificity of antiendothelial cell antibodies. Our study results showed that antiendothelial cell antibodies may play an important role for graft destruction, independent of panel reactive antibody and crossmatch positivity.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    Detection of Donor-Specific Antibodies Both in Serum and Cardiac Allograft Biopsy in Heart Transplant Patients: Tissue DSA is More Predictive than Serum DSA
    (2018) Basturk, Bilkay; Sezgin, Atilla; Sade, Elif; Ozdemir, B. Handan; Terzi, Aysen; Kantaroglu, Bircan; Haberal, Mehmet; 0000-0002-8784-1974; 0000-0002-7528-3557; 0000-0002-1225-1320; 0000-0002-3462-7632; AAD-6918-2021; X-8540-2019; F-7546-2013; AAJ-8097-2021
  • No Thumbnail Available
    Item
    Determination of Cytokine Gene Polymorphisms in a Heart Transplant Patient Resistant to Desensitization Therapy: Case Report
    (2022) Basturk, Bilkay; Kavuzlu, Miray; Khalilova, Afag; Kantaroglu, Bircan; Sezgin, Atilla; https://orcid.org/0000-0002-9288-942X; 35384819; AAE-2689-2021
    Heart transplant is the best treatment option for end-stage heart failure. The major goals in solid-organ transplant are organ survivability and functionality. The effects of anti-HLA antibodies and cytokines are important for immune response. Cytokine gene polymorphisms are also effective during cytokine release. Here, we report a heart transplant recipient who was diagnosed with antibody-mediated rejection posttransplant and had an antibody response resistant to desensitization therapy. After transplant, panel reactive antibody screening and identification class I and II tests and Luminex single antigen class I and II tests were performed. Desensitization treatment included intravenous immunoglobulin, plasmapheresis, rituximab, and bortezomib. Because of these reasons, cytokine gene polymorphism tests (consistent with low, intermediate, and high expression levels for tumor necrosis factor a, transforming growth factor ss 1, interleukin 6 and 10, and interferon.) were conducted. We found polymorphic regions compatible with the high-release, proinflammatory action of tumor necrosis factor a and interleukin 6, which induced inflammation and B-cell activation, and polymorphic regions compatible with the intermediate release of the potent immunosuppres- sive effects of transforming growth factor ss 1 and interleukin 10, suggesting that the patient may not be able to effectively suppress the activation of the immune system. The influence of cytokine gene polymorphism on the formation of a resistant antibody response in a patient, despite desensitization, contributed to the proinflammatory response in which these cytokines were involved.
  • No Thumbnail Available
    Item
    Frequency of Finding Family Donors: A Single Center Experience
    (2018) Kasar, Mutlu; Yeral, Mahmut; Solmaz, Soner; Buyukkurt, Nurhilal; Asma, Suheyl; Gereklioglu, Cigdem; Boga, Can; Ozdogu, Hakan; Basturk, Bilkay; 0000-0003-3856-7005; 0000-0002-9580-628X; 0000-0002-0895-4787; 0000-0001-5335-7976; 0000-0002-8902-1283; 0000-0002-9680-1958; 0000-0002-8784-1974; 29527991; AAL-3906-2021; ABC-4148-2020; AAE-1457-2021; AAI-7831-2021; AAD-6222-2021; AAD-5542-2021; AAD-6918-2021
    Objectives: Allogeneic hematopoietic stem cell transplant is a curative treatment option for many hematologic diseases. The existence of a fully compatible donor for recipients is the first condition for minimized transplant-related mortality and morbidity. The best donor for hematopoietic stem cell transplant is an HLA-matched sibling donor. The possibility of finding an HLA-matched sibling is less than 30% worldwide. Hematopoietic stem cell transplant is needed for an increasing number of patients every year, but the ability to find a fully compatible donor has limited its use. Materials and Methods: From August 2012 to May 2017, we screened 412 adult patients who required AHSCT and their families for HLA tissue groups who were seen at our center (Baskent University Adana Dr. Turgut Noyan Research and Medical Center Hematology Unit). To screen tissue groups at our center, we perform lowresolution typing for HLA-A, B, -C, -DRB1, and -DQB. If an HLA genotype cannot be identified, verification typing is done using high-resolution testing. Results: We found matched family donors in 227 (55%) of 412 patients screened at our center. The ratio of HLAmatched related donors was 83% for 279 patients who received allogeneic stem cell transplant. Conclusions: The likelihood of finding eligible unrelated donors has been gradually increasing, in part due to the development of the National Bone Marrow Bank. However, a careful screening for related donors is still important. Our findings indicate the importance of careful examination of family genealogy and of careful family screening in our region.
  • No Thumbnail Available
    Item
    The Frequency of HLA-A, -B, -C,-DRB1 and-DQB1 alleles in Patients with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
    (2023) Basturk, Bilkay; Kavuzlu, Miray; Kasar, Mutlu; 0000-0002-8784-1974; AAD-6918-2021
  • No Thumbnail Available
    Item
    HLA Sensitization in End-Stage Heart Failure Patients Supported By Extracorporeal Membrane Oxygenation
    (2018) Aliyev, Anar; Ersoy, Ozgur; Gultekin, Bahadir; Beyazpinar, Sarp; Basturk, Bilkay; Sezgin, Atilla; Aslamaci, Sait; 0000-0002-8784-1974; ABA-7388-2021; AAD-6918-2021
  • No Thumbnail Available
    Item
    IgG and IGG4 Positive Plasma Cell Profile in Recurrent Antibody-Mediated Rejection (AMR) of Cardiac Transplants
    (2022) Terzi, Aysen; Basturk, Bilkay; Ozdemir, B. Handan; Kavuzlu, Miray; Sezgin, Atila
  • No Thumbnail Available
    Item
    The Importance of the Histopathological Findings of Surveillance Biopsies in the Monitoring Of Acute Antibody-Mediated Rejection (AMR) In Cardiac Allograft Recipients with or Without Clinical Symptoms: Single Center Experience
    (2018) Terzi, Aysen; Tunca, Zeynep; Ozdemir, B. Handan; Sezgin, Atilla; Basturk, Bilkay; Sade, Elif; Haberal, Mehmet; https://orcid.org/0000-0002-1225-1320; https://orcid.org/0000-0002-7528-3557; https://orcid.org/0000-0002-8784-1974; https://orcid.org/0000-0002-3462-7632; F-7546-2013; X-8540-2019; AAD-6918-2021; AAJ-8097-2021
  • No Thumbnail Available
    Item
    Investigation of miRNA and Anti HLA Antibodies Correlation in Patients with Kidney Transplant
    (2018) Basturk, Bilkay; Sozer, Oktay; Kantaroglu, Bircan; Caliskan, Kenan; Torun, Dilek; Noyan, Aytul; Haberal, Mehmet; 0000-0002-8784-1974; 0000-0002-8767-5021; 0000-0002-6267-3695; 0000-0002-3462-7632; AAD-6918-2021; AAJ-7201-2021; AAD-9111-2021; AAD-5713-2021; AAJ-8097-2021
  • No Thumbnail Available
    Item
    mHLA-G Expression on CD4+CD25(High) T Cell and CD16+Natural Killer Cell Associated with Clinical Status in Renal Transplantation Patients
    (2016) Basturk, Bilkay; Kantaroglu, Bircan; Noyan, Aytul; Arel, Ilker; Tekkarismaz, Nihan; https://orcid.org/0000-0002-8784-1974; https://orcid.org/0000-0001-7631-7395; AAD-6918-2021; AAD-5713-2021; AAD-9088-2021
  • No Thumbnail Available
    Item
    Microvascular Injury With Macrophage, Neutrophil, And Hla-dr Positive Inflammatory Infiltrate, either in dsa Positive or Negative abmr, Determines the Prognosis in Renal Allografts
    (2022) Ozdemir, B. Handan; Basturk, Bilkay; Terzi, Aysen; Sayin, Burak; Haberal, Mehmet; 0000-0002-3462-7632; AAJ-8097-2021
  • No Thumbnail Available
    Item
    The Most Common HLA Alleles and Anti-HLA Antibodies to Know for Virtual Cross-Match
    (2016) Basturk, Bilkay; Kantaroglu, Bircan; Kavuzlu, Miray; Kavuzlu, Miray; Sariturk, Cagla; 0000-0002-8784-1974; 0000-0002-9288-942X; 0000-0002-9288-942X; 0000-0002-4130-1059; 27805512; AAD-6918-2021; AAE-2689-2021; AAE-2689-2021; AAS-7129-2021
    Objectives: Human leukocyte antigens and HLA-specific antibodies are important before and after transplant treatment. The determination of the alloantibodies before transplant is useful for the estimation of risk for antibody-mediated rejection. Virtual crossmatch uses solid-phase assay to detect anti-HLA antibodies and allows exclusion of donors with unacceptable HLA antigens. The aim of our retrospective study was to investigate HLA class I and class II alleles and panel reactive antibody and Luminex Corporation (Austin, TX, USA) single-antigen bead assay positivity frequencies in the Southeastern region of Turkey Material and Methods: Tissue typing results for HLA class I (HLA-A, HLA-B, HLA-C) and class-II (DRB1and DQB1 haplotypes) in 1756 patients and 2951 donors who were at Baskent University Adana Research and Medical Center between 2010 and 2015 for transplant were studied using sequence-specific primers and/or sequence-specific oligonucleotides. Serum samples were analyzed by Luminex bead technology for antibody detection. Results: We found that, for class I, HLA-A*02, HLA-B*35, and HLA-A*24 and, for class II, DRB*11, DRB*01, and DRB*04 were the 4 most common antigens and HLA-A02, B49, A68, B7 were the 3 most common anti-HLA antibodies, with mean fluorescence intensity values >= 2000 in our population group. Human leukocyte antigen alleles and anti-HLA antibodies were compared with each other except HLA-A*02, A2, with no correlations between allele and panel reactive antibody frequencies identified. However, there was a weak correlation between panel reactive anti body-mean fluorescence intensity scores of 5000 and above with Luminex single-antigen bead assay. Conclusions: This study is the first to conduct such a mass screening of a Turkish population. Our study results show that there is no correlation between HLA frequencies and anti-HLA antibody frequencies. However, there was a weak correlation between panel reactive antibody mean fluorescence intensity scores of 5000 and above with Luminex single-antigen bead assay. Of note, this pattern is important to know for virtual cross-match.
  • No Thumbnail Available
    Item
    Pediatric Renal Transplantation: A Single Center Experience
    (2015) Dursun, Hasan; Cengiz, Nurcan; Noyan, Aytul; Caliskan, Kenal; Basturk, Bilkay; Yildirim, Sedat; Moray, Gokhan; Baskin, Esra; Haberal, Mehmet; 0000-0002-5735-4315; 0000-0002-8817-494X; 0000-0003-2498-7287; 0000-0002-3462-7632; 0000-0003-4361-8508; 0000-0002-8784-1974; AAF-4610-2019; AAB-7105-2020; AAE-1041-2021; AAJ-8097-2021; AAD-5713-2021; B-5785-2018; AAD-6918-2021